Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

Source: Cancer Therapy Advisor, June 2018

Results from a small retrospective study published in the Journal of Neuro-Oncology suggest that there could be a survival benefit to combining radiation with certain checkpoint inhibitors to treat patients with melanoma-related brain metastases.1

Researchers identified 38 patients with melanoma brain metastases who had been treated with Gamma Knife radiosurgery at a single care location between 2012 and 2017 who had also initiated treatment with immune checkpoint inhibitors within 8 weeks of surgery. Across the cohort, median progression-free survival (PFS) after 2 years was 3.4 months and median overall survival (OS) was not reached by that time.

read the original full article